We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Loses Top Executive Again, CFO Clancy to Join Alexion
Read MoreHide Full Article
Biogen Inc.’s (BIIB - Free Report) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. next month.
Shares of Alexion were up 3.7% in after-hours trading on Tuesday while Biogen’s shares declined 1.3%. This year, Biogen’s shares have declined 9.9% so far while the Zacks classified Biomed-Genetics industry has gained 2.2%.
Clancy who also held the position of executive vice president, Finance at Biogen will join Alexion on Jul 10 while assuming the role of CFO from Jul 31. He has been with Biogen for 16 years. Prior to that, Clancy served at food/beverage giant PepsiCo, Inc. (PEP - Free Report) in various executive roles for 13 years. Clancy will replace Dave Anderson, who will become a senior adviser to chief executive officer (CEO) Ludwig Hantson. Alexion had announced Anderson’s resignation last month. Anderson will be with Alexion through end of August.
Biogen also announced that its present chief accounting officer, Greg Covino, will serve as the company’s interim principal financial officer, as the search for a new CFO is conducted.
Several key executives at Biogen have departed over the past couple of years, which has given rise to concerns that the company may be in trouble. These include R&D head, Douglas Williams and HR head Kenneth DiPietro in 2015; chief information officer, Matt Griffiths in 2016 and technology head Adriana Karabout in March this year.
Importantly, George A. Scangos resigned as CEO in Jul 2016. He was replaced by present CEO, Michel Vounatsos, who assumed responsibilities in January.
Meanwhile, Alexion appointed its present CEO Hantson in March this year.
A better-ranked stock in the large-cap pharma sector is Bayer Aktiengesellschaft (BAYRY - Free Report) with a Zacks Rank #2 (Buy).
Shares of Bayer have risen 29.1% this year so far while estimates for both 2017 and 2018 have risen around 2% in the past 30 days.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
Biogen Loses Top Executive Again, CFO Clancy to Join Alexion
Biogen Inc.’s (BIIB - Free Report) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. next month.
Shares of Alexion were up 3.7% in after-hours trading on Tuesday while Biogen’s shares declined 1.3%. This year, Biogen’s shares have declined 9.9% so far while the Zacks classified Biomed-Genetics industry has gained 2.2%.
Clancy who also held the position of executive vice president, Finance at Biogen will join Alexion on Jul 10 while assuming the role of CFO from Jul 31. He has been with Biogen for 16 years. Prior to that, Clancy served at food/beverage giant PepsiCo, Inc. (PEP - Free Report) in various executive roles for 13 years. Clancy will replace Dave Anderson, who will become a senior adviser to chief executive officer (CEO) Ludwig Hantson. Alexion had announced Anderson’s resignation last month. Anderson will be with Alexion through end of August.
Biogen also announced that its present chief accounting officer, Greg Covino, will serve as the company’s interim principal financial officer, as the search for a new CFO is conducted.
Several key executives at Biogen have departed over the past couple of years, which has given rise to concerns that the company may be in trouble. These include R&D head, Douglas Williams and HR head Kenneth DiPietro in 2015; chief information officer, Matt Griffiths in 2016 and technology head Adriana Karabout in March this year.
Importantly, George A. Scangos resigned as CEO in Jul 2016. He was replaced by present CEO, Michel Vounatsos, who assumed responsibilities in January.
Meanwhile, Alexion appointed its present CEO Hantson in March this year.
Biogen carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked stock in the large-cap pharma sector is Bayer Aktiengesellschaft (BAYRY - Free Report) with a Zacks Rank #2 (Buy).
Shares of Bayer have risen 29.1% this year so far while estimates for both 2017 and 2018 have risen around 2% in the past 30 days.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>